The U.S. International Trade Commission’s Revision 20 for 2026 is a highly targeted update focused on the administration of trade-remedy programs, not a broad tariff action. The revision’s centerpiece is the establishment of a new Chapter 99 heading, 9903.04.70, which creates a pathway for importers to claim a 0% additional duty on certain pharmaceutical articles and ingredients used for non-commercial applications like clinical trials and research. This change, which affects goods in Chapters 29 and 30, refines an existing Section 232 program rather than creating a new one. The revision contains no changes to standard MFN duty rates and makes only minor adjustments to the product scope of several Chapter 99 programs.
What this revision does
Revision 20 to the 2026 Harmonized Tariff Schedule (HTSUS), effective September 29, 2026, is an administrative and scope-refining update, not a rate-moving one. The revision introduces no changes to Column 1 General (MFN) duty rates. Instead, its 351 distinct changes are concentrated almost entirely in Chapter 99, which governs temporary trade remedies.
The dominant theme is the refinement of a Section 232 program covering pharmaceuticals. The revision establishes a new heading that formalizes an exemption pathway for specific pharmaceutical products, while making only minor net additions to the program’s overall product scope. The changes are overwhelmingly focused on goods in Chapter 30 (Pharmaceutical products) and Chapter 29 (Organic chemicals), signaling a technical adjustment for importers in the life sciences sector rather than a broad shift in U.S. trade policy.
Trade-remedy programs
The bulk of this revision’s activity centers on the structure and scope of Chapter 99 trade-remedy programs, particularly those affecting pharmaceuticals.
New Exemption Pathway for R&D Pharmaceuticals
The most significant change is the establishment of a new Chapter 99 heading, 9903.04.70, under the “Pharmaceuticals (Section 232)” program family. This new heading is not a tariff hike; it provides for a 0% additional duty on top of the product’s standard MFN rate.
Critically, this is an end-use provision. It applies only to “pharmaceutical articles and associated ingredients… that are solely for use in clinical trials, research and development, or other non-commercial applications,” as provided in U.S. Note 40, which this revision amends. This is not an automatic exemption; importers must affirmatively claim the heading at the time of entry and be prepared to substantiate the end use of the goods.
This new heading provides a formal mechanism for claiming an exemption on goods already largely within the program’s purview. It covers 149 distinct HTS subheadings, primarily from Chapters 29 and 30. Of these, 145 were already covered by other headings within the same Section 232 program. This indicates that the new heading primarily serves to reorganize and create a specific administrative pathway for a subset of goods, rather than representing a major expansion of the program itself.
Product Scope Adjustments
Beyond the creation of the new heading, the revision makes several minor adjustments to the product scope of existing Chapter 99 headings:
-
Scope Additions: A total of four distinct HTS codes, all for medicaments in Chapter 30 (HS heading 3004), were newly added to the scope of 14 existing Chapter 99 headings. These four products represent the only net expansion of coverage for the Section 232 pharmaceutical program in this revision.
-
Scope Removals: Ten distinct HTS codes were removed from the scope of various Chapter 99 headings across the pharmaceutical, Brazil Section 301, and other programs. However, this is largely an administrative cleanup. Nine of the ten codes were already-retired statistical numbers that could not be used for entry, meaning their removal has no practical impact on importers. Only one live HTS line was substantively removed from a program’s scope.
These coordinated additions and removals across several programs affecting the same chemical and pharmaceutical products underscore the revision’s character as a technical and statistical housekeeping exercise.
Tariff & line changes
This revision is quiet on the front of ordinary customs duties and tariff classifications.
-
MFN Rates: No changes were made to standard Column 1 General (MFN) duty rates in Chapters 1 through 97. All MFN tariffs on commodity lines remain as they were in the previous revision.
-
Commodity Lines: The revision did not establish or remove any HTS commodity lines or statistical reporting numbers. The underlying structure of the tariff schedule for Chapters 1-97 is unchanged.
What takes effect, and when
The timing of this revision is straightforward. The vast majority of the 351 changes, including the establishment of the new pharmaceutical heading and all related scope adjustments, were introduced in this revision with a load date of September 29, 2026. A small handful of changes were also assigned a formal policy effective date of September 29, 2026, aligning all modifications to the same day.
The policy behind the changes
This revision lands in the same product area as recent policy guidance from the U.S. Department of Commerce. On September 23, 2026, just days before the revision was published, the Department issued guidance on Section 232 tariff exemptions for specialty pharmaceuticals.
That guidance, issued under Presidential Proclamation 11020, defines categories of specialty pharmaceuticals and ingredients eligible for a zero percent tariff rate when they come from jurisdictions with trade and security frameworks. It is related context, not the source of this revision: the HTS revision does not cite it, and the two turn on different things. The Commerce guidance is about product category and origin; heading 9903.04.70 is about end use, namely clinical trials, research and development, or other non-commercial applications. What they share is the product area. The guidance covers organic chemicals under HS headings such as 2918, 2921 and 2922, which also fall within the U.S. Note 40 list.
What to watch
For importers of pharmaceuticals and organic chemical ingredients, particularly those supplying goods for research and development, this revision presents a significant opportunity. The key action item is to review the new heading 9903.04.70 and the accompanying U.S. Note 40 in detail. Companies should assess whether their imported products and their end use in the U.S. meet the criteria for the 0% additional duty.
Because this is an elective, end-use-based provision, the compliance burden rests with the importer. Proactive classification and the maintenance of robust documentation to prove non-commercial use in clinical trials or R&D will be essential for claiming the benefit and defending it against any future CBP inquiries. The ongoing refinements to this Section 232 program suggest it remains an area of active policy management, and importers in this space should anticipate further administrative adjustments.